Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Head & Neck 3Gynecologic 3Genitourinary 2Breast 2Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 1Carcinoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 467Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Indomethacin × Breast × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡